Study identifier:D0542C00001
ClinicalTrials.gov identifier:NCT01560234
EudraCT identifier:N/A
CTIS identifier:N/A
A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects
Healthy
Phase 1
Yes
AZD8848, Placebo
All
47
Interventional
18 Years - 50 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Apr 2016 by AstraZeneca
AstraZeneca
-
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of AZD8848 in healthy subjects.
A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects
Location
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: AZD8848 | Drug: AZD8848 Single dose, oral inhalation (nebuliser solution) |
Placebo Comparator: Placebo | Drug: Placebo Single dose, oral inhalation (nebuliser solution) |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.